Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it will begin joint sales with Denka Co., Ltd. (Denka) of the QuickNavi^TM-Campylobacter antigen diagnostic kit, which is currently marketed by Denka. Otsuka will commence its sales activities on April 3, 2026.

QuickNavi-Campylobacter became the first product in Japan to receive insurance reimbursement in April 2023 as an aid for the diagnosis of Campylobacter infection by detecting Campylobacter antigens in fecal samples. Since December 2023, it has been distributed by its manufacturer, Denka. Otsuka and Denka have collaborated in the joint sales of the in‑vitro diagnostic reagents, QuickNavi series, and with the establishment of a stable supply system now in place for this product, the companies have now decided to commence joint sales.

QuickNavi-Campylobacter is an immunochromatographic assay kit that enables rapid and specific detection of Campylobacter antigens in fecal samples, providing results within 15 minutes. It is used for patients presenting with diarrhea suspected to be caused by Campylobacter infection, in situations where prompt differential diagnosis is required, and allows healthcare providers in Japan to confirm test results on site for the first time. The rapid availability of results is expected to support timely clinical decision‑making and contribute to appropriate antimicrobial therapy. The kit can also utilize the same fecal specimen as the jointly marketed norovirus antigen kit QuickNavi‑Noro 3, enabling efficient differential diagnosis of infectious gastroenteritis.

Otsuka has a long-standing commitment to infectious disease control, having developed and commercialized a treatment for multidrug-resistant tuberculosis as well as diagnostic agents, including those for Helicobacter pylori. Recognizing infectious disease management as an ongoing social responsibility, Otsuka will continue to contribute to prompt and appropriate clinical care through the provision of reliable diagnostic solutions.

About Otsuka

Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. For further information, please visit www.otsuka.co.jp/en/.